Abstract 1205TiP
Background
Extrapulmonary neuroendocrine carcinoma has a poor prognosis with a median survival of about 1 year. The current standard first-line treatment for extrapulmonary neuroendocrine carcinoma is etoposide combined with cisplatin (EP) or etoposide combined with carboplatin (EC). Camrelizumab (anti-PD-1 antibody) and apatinib (VEGFR2-TKI) have shown definite antitumor effects in a variety of solid tumors. The aim of this study is to evaluate the efficacy and safety of camrelizumab combined with EP/EC chemotherapy, followed by camrelizumab plus apatinib as first-line treatment for advanced or metastatic extrapulmonary neuroendocrine carcinoma.
Trial design
This prospective, single-arm, multicenter study plans to enroll 30 patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma who have not been systematically treated. Enrolled patients will receive 4-6 cycles of EP (etoposide 100mg/m2 d1-3 iv+ cisplatin 25mg/m2 d1-3 iv, repeated every 21 days) or EC (etoposide 100mg/m2 d1-3 iv+ carboplatin AUC=5 d1 iv, repeated every 21 days) in combination with camrelizumab (200mg iv d1, repeated every 21 days). Patients with remission or stable disease will receive camrelizumab (200mg, d1, iv, repeated every 21 days) plus apatinib (250mg orally, once daily) as maintainance therapy until disease progression or unacceptable toxicity. Camrelizumab will be administered for a total of 2 years, and patients with stable or remission disease will continue apatinib treatment until disease progression. The primary endpoint of this study is objective response rate (ORR), while secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR) and safety.
Clinical trial identification
NCT05142865.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1794P - Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era
Presenter: Emre Yekeduz
Session: Poster session 14
1795P - China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Gongqian Zeng
Session: Poster session 14
1796P - Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Presenter: Juan Gómez Rivas
Session: Poster session 14
1797P - Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET/CT: Predicting survival in oligometastatic prostate cancer patients
Presenter: Mikaela Dell'Oro
Session: Poster session 14
1800P - Differential tumor gene-expression profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (dn-mCSPC) versus (vs.) mCSPC relapsing after prior localized therapy (PLT-mCSPC)
Presenter: Vinay Mathew Thomas
Session: Poster session 14
1803P - Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with <italic>AR</italic> ligand-binding domain (LBD) mutations
Presenter: Daniel Petrylak
Session: Poster session 14